Sermorelin + Ipamorelin Blend

Description

Sermorelin Properties

CAS Number	86168-78-7
Molar Mass	3357.93 g·mol⁻¹
Chemical Formula	C149H246N44O42S
Synonyms	Sermorelina, 86168-78-7, Sermoreline, Sermorelinum

Ipamorelin Properties

CAS Number	170851-70-4
Molar Mass	711.868 g·mol⁻¹
Chemical Formula	C38H49N9O5
Synonyms	Ipamoreline, Ipamorelina, IPAMORELIN ACETATE

Product Overview of Sermorelin + Ipamorelin Blend

A laboratory-grade peptide combination consisting of Sermorelin + Ipamorelin formulation intended for research purposes only. BC9’s Sermorelin + Ipamorelin blend is not approved for human consumption.

Sermorelin refers to a 29-amino-acid analogue of the naturally occurring growth hormone-releasing hormone (GHRH). It is believed to engage GHRH receptors and drive pituitary GH-axis signaling in experimental systems.

On the other hand, Ipamorelin is a selective growth-hormone secretagogue (a ghrelin-receptor/GHS-R agonist) with a unique receptor profile. This feature is believed to evoke GH-axis activity through the ghrelin pathway.

When studied together in laboratory models, these compounds may activate complementary hypothalamic-pituitary signaling routes. By doing so, they potentially produce larger or more sustained GH-axis responses.  The mentioned effect was observed in vitro or in animal models.

Why Choose BC9 to Buy Sermorelin + Ipamorelin Blend

BC9 specializes in supplying high-quality peptides and other related research reagents. They come with documentation and lab-grade handling standards. If your study requires a sermorelin ipamorelin blend for bench or preclinical work, BC9 is here to meet your needs.

Researchers looking to buy sermorelin ipamorelin online and explore combinations such as ipamorelin and sermorelin together often seek a single vial solution. This is where BC9 stands out because not only do we sell such a product, but it even comes with a bacteriostatic water so that you are ready to begin your study.

Moreover, we understand that labs studying interactions between sermorelin and ipamorelin find value in a standardized blend. As such, this blend has undergone rigorous quality standard testing to meet such a requirement.

Also, researchers comparing ipamorelin-sermorelin blend effects across models can also benefit from a pure and potent formulation. To meet this demand, each vial is supplied with an updated certificate of analysis (COA) to ensure product quality and effectiveness.

Here are other reasons why BC9 is a reliable supplier of research-based products:

• Responsive and knowledgeable customer support
• Complete and comprehensive product inventory
• Research-grade items
• Free shipping in the US (Orders must be above $150)
• Several payment methods 

Sermorelin + Ipamorelin Blend: Potential Research Applications

Ghrelin-like Activity in Research Models

Ipamorelin functions as a selective agonist for the ghrelin receptor (GHS-R1a). This explains why the research peptide may act as a ghrelin mimetic in experimental systems. Researchers can investigate its molecular signaling effects. This includes receptor activation and the downstream pathway modulation. [1]

When combined with sermorelin, investigators can learn how ghrelin-mimic activity interacts with GHRH-influenced pathways.

Observed Effects on Fat Metabolism in Preclinical Setups

Preclinical models have shown that stimulating both the GHRH and ghrelin receptor pathways may alter lipid metabolism and fat storage. The peptide blend offers a new way to study whether dual-pathway activation changes markers of adiposity, fatty acid oxidation, or body composition. The mentioned effects could be observable in animal or cell-based experiments. [2]

Muscle Growth Pathways Under Investigation

Because GH-axis signaling influences muscle development, the sermorelin + ipamorelin blend may be used in models exploring muscle protein synthesis, satellite cell activation, and lean mass retention. [3]

In certain preclinical studies, the growth hormone-releasing hormone (GHRH) pathway and the ghrelin receptor pathway have both been shown to influence metabolism. Once activated, the mentioned pathways encourage growth hormone release, which in turn modulates downstream signals, insulin-like growth factor 1 (IGF-1), and other metabolic factors.

Neuroendocrine Links to Sleep Patterns

Growth hormone release is tightly linked with circadian rhythm and sleep regulation. In most mammalian models, the largest GH pulses are observed during sleep. This is specifically occurring during the early phases of slow-wave (deep) sleep. [4]

As such, researchers may utilize this blend to determine how dual stimulation of GHRH and ghrelin pathways impacts the following:

• Neuroendocrine signaling
• Sleep-associated hormone pulses
• Circadian biology among animal models

Skeletal and Bone Density

The growth hormone (GH)/insulin-like growth factor (IGF) axis plays a central role in skeletal biology. In preclinical studies, GH signaling has been shown to stimulate osteoblast activity (bone-forming cells), increase collagen synthesis, and enhance bone matrix deposition. [5]

BC9’s Sermorelin + Ipamorelin blend becomes a useful research tool for examining the hormonal regulation of lipid metabolism, adiposity, and energy partitioning within controlled research environments.

IMPORTANT: The potential applications mentioned above are the results of laboratory-based experiments and research studies. These have not proven to be applicable to humans. The Sermorelin + Ipamorelin Blend is not approved for human consumption. It is sold solely for research purposes.

Frequently Asked Questions

Why are sermorelin and ipamorelin blended together in research settings?

Researchers blend a GHRH analogue (sermorelin) with a ghrelin-receptor agonist (ipamorelin) to investigate dual pathway activation of the GH axis.

What should I look for if I want to buy an ipamorelin-sermorelin blend?

When procuring research products, it is essential to choose suppliers who possess the following characteristics:

• Third-party lab-tested products
• Responsive and knowledgeable customer service
• Clear labeling of “Laboratory Research Use Only”
• Competitive pricing
• Extensive inventory

All of these are qualities BC9 has, making it your go-to supplier for every research product you require. Including our Sermorelin + Ipamorelin blend.

Is BC9’s Sermorelin + Ipamorelin blend safe for human use?

No, this product is not FDA-approved for human consumption. The BC9 team sells its Sermorelin + Ipamorelin blend for research studies only.

How should I store this peptide formulation?

Store this peptide formulation in a cool, dry place, away from direct sunlight. Lyophilized peptides are stable for 12–24 months when stored at –20°C or lower. Once reconstituted, the solution should be stored in a refrigerator (2–8°C) and used within 2–4 weeks, depending on solvent and handling conditions.

What is this blend being studied for?

In laboratory and preclinical research, the blend is used to investigate a range of processes, such as the following:

• Ghrelin-like signaling
• Fat metabolism and adiposity
• Muscle biology
• Bone biology

References:

1. Casanueva, F. F., Camiña, J. P., Carreira, M. C., Pazos, Y., Varga, J. L., & Schally, A. V. (2008). Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proceedings of the National Academy of Sciences of the United States of America, 105(51), 20452–20457. https://doi.org/10.1073/pnas.0811680106 
2. Notaro, N. M., & Dyck, D. J. (2024). Regulation of peripheral tissue substrate metabolism by the gut-derived hormone ghrelin. Metabolism Open, 21, 100279. https://doi.org/10.1016/j.metop.2024.100279 
3. Perrini, S., Laviola, L., Carreira, M. C., Cignarelli, A., Natalicchio, A., & Giorgino, F. (2010). The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. Journal of Endocrinology, 205(3), 201–210. https://doi.org/10.1677/JOE-09-0431 
4. Kim, T. W., Jeong, J.-H., & Hong, S.-C. (2015). The Impact of Sleep and Circadian Disturbance on Hormones and Metabolism. International Journal of Endocrinology, 2015(591729), 1–9. https://doi.org/10.1155/2015/591729
5. Lindsey, R. C., & Mohan, S. (2016). Skeletal Effects of Growth Hormone and Insulin-like Growth Factor-I Therapy. Molecular and Cellular Endocrinology, 432, 44–55. https://doi.org/10.1016/j.mce.2015.09.017